# Medicud Srl

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medicud

- Industry: Medical Devices & Equipment
- Headquarters: Rome, Italy
- Website: www.medicud.it
- Total disclosed funding: $0.8M
- Latest round: Seed (Apr 1, 2025)
- Investors on record: 3

## About

Medicud Srl develops innovative medical devices, primarily focusing on advanced wound care solutions that enhance healing processes and improve patient outcomes.Medicud Srl, founded in 2020 in Rome, Italy, specializes in medical devices that provide innovative solutions for wound care. The company launched its flagship product, Dryum, which is a single-use, mechanically powered incisional negative pressure wound therapy device. Medicud has successfully completed 3 deals and is not known to have undergone any significant changes in business strategy or operations. The company was founded by individuals whose specific identities are not publicized. The latest funding round occurred on April 9, 2025, where Medicud raised EUR 0.766 mn in SEED funding, led by CHMBR Partners LLC, with other investors including 50 Partners and BADGE Business Angels des Grandes Ecoles. To date, Medicud has raised a total of EUR 0.766 mn in funding.Medicud specializes in innovative medical devices, primarily focusing on a single-use, mechanically powered incisional negative pressure wound therapy (i-NPWT) device known as Dryum. Launched in 2020, Dryum provides a user-centered, ultraportable solution designed to deliver constant negative pressure to surgical wounds, thereby reducing complications and enhancing healing. This device addresses specific challenges in wound care, such as high costs and the cumbersome nature of existing therapies, ultimately aiming to improve patient outcomes. Medicud targets a diverse client base that includes healthcare providers, hospitals, and surgical centers in multiple geographical markets, expanding beyond Italy to potential markets across Europe and other regions with significant surgical activity.Medicud operates on a direct-to-consumer and B2B transaction model, primarily selling its flagship product, Dryum, to healthcare institutions and professionals. The company’s revenue structure involves direct sales to hospitals and clinics, leveraging partnerships for distribution in various markets. The anticipated market entry for Dryum is set for 2025, targeting a segment of the substantial market of over 230 million incisional surgeries performed annually worldwide. Revenue generation aligns with the growing demand for effective and sustainable wound care solutions, enabling Medicud to potentially establish long-term contracts or recurring purchasing agreements with healthcare providers looking to improve surgical care.Medicud plans to launch its flagship product, Dryum, in 2025, following its market entry and the completion of regulatory approvals for the CE mark and FDA certification. The recent funding of EUR 0.766 mn raised on April 9, 2025, will support the market launch of Dryum and facilitate the necessary regulatory processes. Additionally, Medicud aims to expand into European markets and other regions with significant surgical activities, capitalizing on the demand for advanced wound care solutions.

## Funding rounds

- Seed, Apr 1, 2025, $0.8M — 50 Partners, BADGE Business Angels des Grandes Ecoles, CHMBR Partners LLC

## Investors

- 50 Partners (https://capitalatlas.ai/funds/50-partners) — Seed
- BADGE Business Angels des Grandes Ecoles — Seed
- CHMBR Partners LLC — Seed